Glaukos Reports Positive Three-Year Phase 3 Extension Results for Epioxa in Keratoconus Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company developing innovative therapies for glaucoma, corneal disorders and retinal diseases, has announced positive topline results from a…
Medisca and EUROAPI Form Strategic Partnership to Expand API Access for Pharmaceutical Compounding Medisca and EUROAPI have entered into a strategic partnership designed to expand access to active pharmaceutical ingredients (APIs) for the pharmaceutical compounding market, with an initial focus…
Dexcom Launches Fifth Season of Dexcom U NIL Program for College Athletes With Diabetes Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, has launched the fifth season of Dexcom U, its Name, Image and Likeness (NIL) program created…
GE HealthCare to Acquire SOFIE Biosciences for $945 Million to Expand U.S. Radiopharmaceutical Manufacturing GE HealthCare (Nasdaq: GEHC) has announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based contract manufacturing organization (CMO) specializing in PET radiopharmaceuticals, from Trilantic…
Catalent Launches Accelerated U.S. Gene-to-Drug Substance Program for Complex Biologics Catalent, Inc., a global contract development and manufacturing organization (CDMO) serving the biopharmaceutical industry, has announced the U.S. launch of an accelerated gene-to-drug substance program designed to help developers advance…
Pfizer Reports Positive Phase 3 Results for LITFULO in Nonsegmental Vitiligo Pfizer Inc. (NYSE: PFE) has announced detailed results from two Phase 3 clinical trials evaluating LITFULO® (ritlecitinib) as a once-daily oral treatment for people living with nonsegmental vitiligo (NSV).…
ILiAD Biotechnologies Publishes Phase 2b SUPER Trial Results for Intranasal Pertussis Vaccine Candidate BPZE1 in The Lancet Infectious Diseases ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical-stage biotechnology company focused on preventing and treating diseases caused by Bordetella pertussis, has announced…
Italfarmaco and JCR Pharmaceuticals Enter Exclusive Agreement to Advance JR-141 for Hunter Syndrome in Global Markets Italfarmaco S.p.A. and JCR Pharmaceuticals Co., Ltd. (TSE: 4552) have entered into an exclusive license agreement to develop and commercialize JR-141, an investigational blood-brain…
ICUS Review Finds No State Law Explicitly Bans Credentialed Sonographers From Administering Ultrasound Contrast The International Contrast Ultrasound Society (ICUS) has released a comprehensive review of statutes and regulations covering all 50 U.S. states and the District of Columbia, challenging…
City of Hope Study Links High Sugar Intake to Greater Antibiotic-Related Gut Microbiome Disruption Researchers at City of Hope, a major cancer research and treatment organization, have reported new findings suggesting that consuming higher amounts of sugar during antibiotic treatment…
RestorixHealth Announces Center Recognition Award Recipients for January–June 2026 RestorixHealth, a wound care solutions company focused on improving outcomes for patients with complex and chronic wounds, has announced the recipients of its Center Recognition Awards for the January–June 2026 awards…
Aptatek Biosciences Secures Financing to Advance PheCheck Home-Based PKU Monitoring System Aptatek Biosciences, Inc., a clinical-stage diagnostics company developing connected technologies for decentralized metabolic monitoring, has announced the initial close of a financing round led by Canterbury Scientific Ltd. and…